EUCTR2017-003334-82-DE进行中（未招募）1 期
Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial - AER
niversity of Cologne0 个研究点目标入组 26 人开始时间: 2019年1月2日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Relapsed/refractory cHL with progression while treated with an anti-PD1 antibody or
- •Relapsed/refractory cHL with stable disease for > 6 months as best response to ongoing anti-PD1 antibody therapy
- •- At least two distinct FDG-avid HL-lesions with at least 5cm distance between them, and one of them considered eligible for irradiation with 20Gy
- •- One but the irradiated lesion has to be outside the 10% isodose in RT planning confirmed by the Central Response Evaluation Panel (CREP)
- •- Age =18 years, all sexes
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 26
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Nodular lymphocyte-predominant HL or grey-zone lymphoma
- •- Evidence of active, non-infectious lung disorder with DLCOc <50%
- •- History of long-term or ongoing ingestion of immunosuppressive agents >10mg prednisone/d
- •- Any other serious disease or organ dysfunction which might impair protocol treatment
研究者
相似试验
进行中（未招募）
1 期
Effect of Radiotherapy and Nivolumab in Relapsed classical Hodgkin LymphomaImprovement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy.MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-003334-82-ATniversity of Cologne26
进行中（未招募）
1 期
Effect of Radiotherapy and Nivolumab in Relapsed classical Hodgkin LymphomaImprovement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy.MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-003334-82-NLniversity of Cologne29
进行中（未招募）
1 期
Effect of Radiotherapy and Nivolumab in Relapsed classical Hodgkin LymphomaImprovement of efficacy of nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma who recently progressed on anti-PD1 therapy.MedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-003334-82-NOniversity of Cologne29
招募中
2 期
AERN study: Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trialHodgkin's diseasemallignant lymphoma10025319Hodgkin LymphomaNL-OMON54697niversity of Cologne3
已完成
不适用
Effect of short-course radiotherapy followed by neoadjuvant Xelox (Capecitabine and Oxaliplatin) chemotherapy and total mesorectal excision in MRI defined high-risk rectal cancer: A phase II trialKCT0003367Yonsei University Health System, Severance Hospital31